









Markets
/
Stocks
/
nasdaq-gmab
/

Genmab A/S

GMAB

28.280USD

+0.240+0.86%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

1.79BMarket Cap

0.52P/E TTM



Genmab A/S

28.280

+0.240+0.86%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

29 / 506

Overall Ranking

107 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 12 analysts

Buy

Current Rating

31.478

Target Price

+12.26%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 49.53% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 44.96.

Overvalued

The company’s latest PE is 1.59, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 65.30M shares, decreasing 8.69% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 2.77M shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 8.97, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is high.

Score

Industry at a Glance

Previous score

8.97

Change



Financials

9.43

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.62

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

9.24

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.58

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 3.40, which is higher than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is 1.57, which is -19.29% below the recent high of 1.27 and 26.53% above the recent low of 1.16.

Score

Industry at a Glance

Previous score

3.40

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 29/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.00, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Genmab A/S is 30.80, with a high of 46.00 and a low of 23.50.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 12 analysts

Buy

Current Rating

31.478

Target Price

+12.26%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Genmab A/S

GMAB

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 9.26, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 29.76 and the support level at 25.30, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.26

Change

0.09

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.054

Neutral

RSI(14)

71.761

Buy

STOCH(KDJ)(9,3,3)

60.654

Neutral

ATR(14)

0.563

Low Volatility

CCI(14)

89.986

Neutral

Williams %R

14.762

Overbought

TRIX(12,20)

0.852

Sell

StochRSI(14)

53.005

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

28.126

Buy

MA10

28.016

Buy

MA20

26.815

Buy

MA50

24.164

Buy

MA100

22.601

Buy

MA200

21.632

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 10.31%, representing a quarter-over-quarter decrease of 1.05%. The largest institutional shareholder is James Simons, holding a total of 2.77M shares, representing 0.44% of shares outstanding, with 50.10% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

AllianceBernstein L.P.

14.73M

-1.41%

Orbis Investment Management Ltd.

5.71M

+102.83%

Citadel Advisors LLC

4.43M

+43.16%

Arrowstreet Capital, Limited Partnership

1.37M

+4398.73%

Two Sigma Investments, LP

3.87M

+15.29%

Harding Loevner LP

2.88M

+28.41%

Renaissance Technologies LLC

Star Investors

2.26M

+17.45%

BlackRock Institutional Trust Company, N.A.

2.95M

-12.82%

Marshall Wace LLP

2.18M

+94.38%

First Trust Advisors L.P.

1.71M

+3.98%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 5.61, which is higher than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.95. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.